尿酸载体URAT1的分子基础 痛风药物抑制尿酸1的抑制
Yang Suo1, Justin G Fedor1, Han Zhang2
1Department of Biochemistry, Duke University School of Medicine, Durham, North Carolina, 27710, USA.
研究人员揭示了URAT1抑制对痛风和高尿血症治疗的分子基础. 了解抑制剂如何与尿酸转运体1 (URAT1) 结合,可以改善药物设计.
科学领域:
- 结构生物学 结构生物学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 超尿血,以血尿酸升高为特征,与痛风和其他疾病有关.
- 人类的尿酸转运体1 (URAT1) 在脏中重新吸收尿酸,使其成为关键的治疗点.
- 现有的URAT1抑制剂由于未知的分子抑制机制而存在局限性.
研究的目的:
- 通过临床相关药物阐明URAT1抑制的分子机制.
- 为开发用于痛风和高尿素血症的新型URAT1抑制剂提供结构性见解.
主要方法:
- 低温电子显微镜 (cryo-EM) 用于单独和使用抑制剂确定URAT1结构.
- 功能实验和分子动力学模拟来分析抑制剂相互作用.
- 对抑制剂依赖的URAT1结构和相互作用网络的分析.
主要成果:
- 确定URAT1与博马龙,莱西努拉德和TD-3复合体中的冷EM结构.
- 证明了抑制剂对向内开放的URAT1状态的选择性结合.
- 确定了独特的抑制剂特定的URAT1构造和影响药物特异性的相互作用网络.
结论:
- 这项研究揭示了URAT1抑制的一般机制.
- 结构和功能方面的见解为设计下一代URAT1抑制剂铺平了道路.
- 这些发现为改善高尿血和痛风治疗提供了基础.
更多相关视频
14:57Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases
Published on: October 10, 2020
08:46Regioselective O-Glycosylation of Nucleosides via the Temporary 2',3'-Diol Protection by a Boronic Ester for the Synthesis of Disaccharide Nucleosides
Published on: July 26, 2018
相关概念视频
Drug Elimination by Renal Route: Tubular Secretion
Renal Drug Excretion: Tubular Secretion
Phase II Reactions: Glucuronidation
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Drug Metabolism: Phase II Reactions
Drug Elimination by Renal Route: Tubular Reabsorption
![Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F61682.jpg&w=3840&q=50)